A European retrospective multicenter analysis (n = 364) comparing ICI therapy between NRAS mutant and wild-type melanomas showed a shorter median OS in patients with NRAS mutations (21 months compared to 33 months) despite similar response rates. Here, NRAS is linked to melanoma.